十种口服抗菌剂对呼吸道病原体的体外活性比较。 - Suppr | 超能文献

A comparison of in vitro activity of ten oral antimicrobial agents against respiratory tract pathogens.

作者信息

Platsouka E, Constantoulaki S, Dimitropoulos N, Niha M, Pierros N, Dimopoulou H, Paniara O

机构信息

Dept. of Microbiology, "Evangelismos" Hospital, Athens, Greece.

出版信息

J Chemother. 1995 Nov;7 Suppl 4:58-60.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

A comparison of in vitro activity of ten oral antimicrobial agents against respiratory tract pathogens.十种口服抗菌剂对呼吸道病原体的体外活性比较。

J Chemother. 1995 Nov;7 Suppl 4:58-60.

2

Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.新型大环内酯类药物氟红霉素对流感嗜血杆菌、肺炎链球菌、化脓性链球菌、卡他莫拉菌和金黄色葡萄球菌的抗菌活性。

J Chemother. 1989 Jul;1(4 Suppl):203-4.

3

In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.莫西沙星对卡塔尔社区呼吸道病原体的体外活性。

Int J Antimicrob Agents. 2004 Sep;24(3):309-10. doi: 10.1016/j.ijantimicag.2004.05.002.

4

Activity of oral beta-lactam antimicrobial agents versus respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the era of antibiotic resistance.抗生素耐药时代口服β-内酰胺类抗菌药物对肺炎链球菌、流感嗜血杆菌和卡他莫拉菌呼吸道分离株的活性

Otolaryngol Head Neck Surg. 2002 Dec;127(6 Suppl):S17-23. doi: 10.1067/mhn.2002.130029.

5

Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.阿莫西林/克拉维酸药代动力学增强型口服制剂（2000/125毫克，每日两次）对2000年全球收集的9172株呼吸道分离菌的体外活性比较

Int J Infect Dis. 2004 Nov;8(6):362-73. doi: 10.1016/j.ijid.2004.02.005.

6

Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.细菌呼吸道病原体的耐药性追踪：2001 - 2005年TRUST监测计划的结果总结

Postgrad Med. 2008 Sep;120(3 Suppl 1):8-15. doi: 10.3810/pgm.2008.09.suppl52.279.

7

Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective.常见呼吸道病原体的抗菌药物敏感性概况：全球视角

Postgrad Med. 2008 Sep;120(3 Suppl 1):16-24. doi: 10.3810/pgm.2008.09.suppl52.280.

8

[In vitro activity of trovafloxacin in 238 respiratory pathogens].[曲伐沙星对238种呼吸道病原体的体外活性]

Rev Esp Quimioter. 1998 Mar;11(1):47-51.

9

Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).住院呼吸道感染患者细菌分离株的药敏模式（MOXIAKTIV研究）

Int J Antimicrob Agents. 2009 Jan;33(1):52-7. doi: 10.1016/j.ijantimicag.2008.07.017. Epub 2008 Oct 1.

10

Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.加拿大流感嗜血杆菌、肺炎链球菌和卡他莫拉菌分离株的抗菌药敏性测定。加拿大抗菌研究小组。

J Antimicrob Chemother. 1999 Mar;43 Suppl A:25-30.

引用本文的文献

1

Azithromycin. A review of its use in paediatric infectious diseases.阿奇霉素。其在儿科传染病中应用的综述。

Drugs. 1998 Aug;56(2):273-97. doi: 10.2165/00003495-199856020-00014.

2

Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.克拉霉素。免疫功能正常患者呼吸道感染治疗中其疗效的综述。

Drugs. 1997 Jun;53(6):973-1004. doi: 10.2165/00003495-199753060-00006.